-+ 0.00%
-+ 0.00%
-+ 0.00%

ASCLETIS' ORAL SMALL MOLECULE GLP-1, ASC30, DEMONSTRATED PLACEBO-ADJUSTED HBA1C REDUCTION OF 1.7% AT 12 WEEKS FROM ITS U.S. PHASE II STUDY IN PARTICIPANTS WITH DIABETES

路透·10/28/2026 23:40:03

请登录查看新闻详情